STUDY OF LABORATORY BIO MARKERS, CT SEVERITY IN PATIENTS MORTALITY DUE TO COVID19 AT TERTIARY CARE HOSPITAL

Abstract

Background: Laboratory biomarkers/radiological ndings are less expensive, faster and easier to obtain. As such, they have been the preferred modality to monitor and predict outcomes and prognosis of COVID 19. Present study was aimed to study laboratory bio markers, CT severity in patients, had mortality due to COVID19 at tertiary care hospital. Material and Methods: Present study was single-center, retrospective, case record based study, conducted among case records of patients of age ≥15 yrs, with COVID RT-PCR positive (oropharyngeal or nasopharyngeal swab) or HRCT-CHESTsuggestive of COVID 19. Results:Among 100 patients, died due to COVID 19 related complications. majority of patients were elderly, from > 64 years age group (55 %), male gender (68 %) had pre-existing morbidity such as Diabetes (53 %), Cardiovascular disease/ Hypertension (25 %), Chronic lung disease (11%). Complications such as Acute Respiratory Distress Syndrome (81 %), Septic shock (65 %), Disseminated Intravascular Coagulation (47 %), Acute Kidney Injury (17 %), Myocardial infarction (17 %) & Liver failure (11 %) were noted among non-survivor patients. Mortality was noted more in 06-10 days (37 %), followed by 11-15 days (26 %), 15-25 days (24 %), ≤ 5 days (9 %) & least was among admitted >25 days (4 %). In patients not survived in COVID 19 infection, raised levels of white blood cell count, neutrophils count, PT, aPTT, serum potassium, direct bilirubin, indirect bilirubin, total bilirubin, AST, ALT, LDH, CRP, D-dimer & procalcitonin while reduced levels of platelets, PaO2 (mmHg), SpO2 (%) were noted. Conclusion: Raised levels of white blood cell count, neutrophils count, PT, aPTT, serum potassium, direct bilirubin, indirect bilirubin, total bilirubin, AST, ALT, LDH, CRP, D-dimer & procalcitonin. while reduced levels of platelets, PaO2 (mmHg), SpO2 were major laboratory bio markers/CTseverity in patients who had mortality due to COVID19